Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.
Recent court rulings and USPTO guidance reshape how biotech startups should approach patent strategy for drugs and ...
Flagship has merged 3 of its own portfolio companies into a single powerhouse aimed at predicting how drugs will work before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results